Biotech | July 08, 2025
Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Subscribe To Our Newsletter & Stay Updated
